Glycopyrronium bromide/formoterol
| Combination of | |
|---|---|
| Glycopyrronium bromide | Muscarinic anticholinergic |
| Formoterol | Long-acting β2 agonist (LABA) |
| Clinical data | |
| Trade names | Bevespi Aerosphere |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth (inhalation) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Glycopyrronium bromide/formoterol, sold under the brand name Bevespi Aerosphere, is a combination medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[2][3] It is a combination of glycopyrronium bromide and formoterol. It is inhaled.[2][3]
The most common side effects include headache, nausea (feeling sick), muscle spasms and dizziness.[3]
Glycopyrronium bromide is a muscarinic receptor antagonist.[3] This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs.[3] Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.[3]
Formoterol is a long-acting beta-2 agonist.[3] It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways.[3] When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open.[3]
Medical uses
[edit]Glycopyrronium bromide/formoterol is indicated as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).[3]
History
[edit]Glycopyrronium bromide/formoterol was approved for medical use in the United States in April 2016,[4] and in the European Union in December 2018.[3]
It is marketed by AstraZeneca.[2][3]
References
[edit]- ^ "Regulatory Decision Summary for Bevespi Aerosphere". 23 October 2014.
- ^ a b c d "Bevespi Aerosphere- glycopyrrolate and formoterol fumarate aerosol, metered". DailyMed. 29 May 2019. Retrieved 8 May 2020.
- ^ a b c d e f g h i j k l m "Bevespi Aerosphere EPAR". European Medicines Agency (EMA). 18 October 2018. Retrieved 8 May 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol". U.S. Food and Drug Administration (FDA). 16 February 2018. Retrieved 8 May 2020.
Further reading
[edit]- Al-Salama ZT, Frampton JE (September 2019). "Glycopyrronium/Formoterol: A Review in COPD". Drugs. 79 (13): 1455–1466. doi:10.1007/s40265-019-01186-x. PMID 31468315. S2CID 201655987.
- D'Urzo AD, Cazzola M, Hanania NA, Buhl R, Maleki-Yazdi MR (2018). "New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology". Int J Chron Obstruct Pulmon Dis. 13: 2805–2819. doi:10.2147/COPD.S113306. PMC 6135066. PMID 30233171.
{{cite journal}}: CS1 maint: overridden setting (link)
